Compugen Ltd. (NASDAQ:CGEN)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.59 and traded as high as $4.33. Compugen shares last traded at $4.24, with a volume of 7,581 shares traded.

Separately, Zacks Investment Research upgraded shares of Compugen from a “hold” rating to a “strong-buy” rating and set a $3.75 price objective for the company in a report on Thursday, August 8th.

The company has a debt-to-equity ratio of 0.11, a current ratio of 5.38 and a quick ratio of 5.38. The stock’s fifty day simple moving average is $3.66 and its 200-day simple moving average is $3.59. The company has a market capitalization of $213.88 million, a P/E ratio of -10.32 and a beta of 2.58.

Compugen (NASDAQ:CGEN) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.04. On average, research analysts predict that Compugen Ltd. will post -0.45 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in the business. ARK Investment Management LLC boosted its holdings in Compugen by 3.2% during the second quarter. ARK Investment Management LLC now owns 8,496,641 shares of the biotechnology company’s stock valued at $32,627,000 after acquiring an additional 267,086 shares during the period. Nikko Asset Management Americas Inc. boosted its holdings in Compugen by 84.0% during the second quarter. Nikko Asset Management Americas Inc. now owns 1,631,037 shares of the biotechnology company’s stock valued at $6,263,000 after acquiring an additional 744,447 shares during the period. Morgan Stanley boosted its holdings in Compugen by 2.1% during the second quarter. Morgan Stanley now owns 1,035,175 shares of the biotechnology company’s stock valued at $3,975,000 after acquiring an additional 21,368 shares during the period. Taylor Frigon Capital Management LLC boosted its holdings in Compugen by 11.5% during the second quarter. Taylor Frigon Capital Management LLC now owns 760,424 shares of the biotechnology company’s stock valued at $2,920,000 after acquiring an additional 78,278 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Compugen by 20.7% during the second quarter. Renaissance Technologies LLC now owns 557,800 shares of the biotechnology company’s stock valued at $2,142,000 after acquiring an additional 95,500 shares during the period. Institutional investors own 29.95% of the company’s stock.

About Compugen (NASDAQ:CGEN)

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

Read More: The basics of gap trading strategies

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.